Physician profile
Tricia Griffiths
NPI 1174938740
$11,944.96
in general payments reported to CMS, 2019-2025
15 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.25 · 2021: $341 · 2022: $842 · 2023: $9,331 · 2024: $601 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,000 · Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.00 |
| Food and Beverage | $1,675.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,771.08 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $577.67 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $418.44 | 2024-2025 | Nucala |
| Medtronic, INC. | $200.99 | 2021-2022 | |
| Genzyme Corporation | $180.99 | 2024-2025 | |
| Insmed, INC. | $164.73 | 2021-2025 | Arikayce |
| Viatris Specialty LLC | $136.42 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $99.03 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.70 | 2023 | |
| Genentech USA, INC. | $86.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $72.73 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $62.67 | 2025 | Glassia |
| Amgen INC. | $40.62 | 2025 | Tezspire |
| Liquidia Technologies, INC. | $30.58 | 2025 | Yutrepia |
| Lilly USA, LLC | $14.06 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Griffiths listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.